Formulation of Peptide:pDNA Nanoparticles
The optimization of the peptide:pDNA formulation was initially based on screening the favorable stoichiometry of the polycationic peptide nitrogen to the polyanionic pDNA phosphorous (1:1-20:1, N:P) mole ratios that promotes stable peptide:pDNA ionic complex formation in annealing (50 mM Tris-HCl and 150 mM NaCl, pH 7.5) buffer. An agarose gel-shift electrophoretic mobility assay in between peptide (polyarginine CPP, R9, vs. CTP-CPP, W-R9) and the pUC19 (2,686 base-pair) pDNA vector, revealed complete disappearance of the pDNA band alone and formation of a more retained complex with excess (10-20:1) N:P peptide:pDNA ratios that effectively form stable ionic complexes (Fig. 2A). This provides a binary approach for confirming the ideal N:P stoichiometric ratio in buffer, by demonstrating formation of the more retained, higher-order peptide:pDNA ionic complex that also excludes external dye (ethidium bromide) binding and staining of the pDNA vector. A similar outcome was observed with the FITC-labeled R9 peptide and the larger (4,361 base-pairs) pBR322 pDNA, that also suggests samples in unbound (FITC-R9) vs. bound (FITC-R9:pDNA) states, highlighting the versatility of the peptides to form stable complexes with various-sized vectors (Fig. 2B). Interestingly, these results also show that the hydrophilic, polycationic R9 CPP can effectively form stable ionic complexes with pUC19 at a 1:1 N:P ratio, presumably due to the unimpeded electrostatic interactions, while the amphiphilic W-R9 CTP-CPP requires a 10:1 N:P ratio to form the stable peptide:pDNA complex (Fig. 2A). The hydrophobic GRP78-targeting W peptide sequence may hinder the formation of stable peptide:pDNA ionic complexes at stoichiometric equivalence. However, this limitation is overcome with excess peptide:pDNA N:P ratios, while the amphiphilic nature of the W-R9 peptide may also enable more favorable csGRP78 receptor and membrane interactions for gene delivery (Lozanda et al. 2023 and Alkhamy et al. 2016).24,25
An optimal N:P stoichiometric ratio is thus essential for achieving efficient peptide condensation of pDNA, while maintaining peptide:pDNA ionic complex stability that may also ensure protection against enzymatic degradation that prolongs transfection efficiency. The stability of the peptide:pDNA complex was next investigated against enzymes such as nucleases or proteases present within serum containing media used in cell culture transfection conditions (Adami et al. 1998).26 The peptide:pDNA samples were incubated in Eagle’s Minimal Essential Medium (EMEM) containing 10% fetal bovine serum (FBS), and aliquots at various time points (1-24 h.) were collected and analyzed on agarose gel electrophoresis (Fig. 2C). The stability of pUC19 in FBS:EMEM at short (1 h.) and extended (24 h.) incubation times indicated some changes in the integrity of the pDNA band, by the appearance of more-retained, smear of bands with slower electrophoretic mobility on gel vs. pUC19 alone (Fig. 2C). This may be an indication of nick(s) in the pDNA resulting in the formation of linear, knotted or catenated DNA structures that transitions circular into open-chained DNA with slower electrophoretic mobility compared to the unnicked condensed circular pDNA vector (Cebrian et al. 2015).27 This outcome confirms that the pDNA is unstable in the FBS-containing media conditions. In contrast, the peptide:pDNA complex (W-R9:pUC19) shows good stability in FBS:EMEM throughout the entire 24 hour incubation period (Fig. 2C). This sample displayed only very faint, slower moving pDNA bands, with no visible changes in intensities over the 24-hour incubation period in FBS:EMEM. The faint bands may be due to minimal quantities of unbound pDNA, that were absent of stable ionic complex with peptide and enzyme exposed for degradation. However, the W-R9 peptide sufficiently forms stable ionic complex with pDNA and provides substantial protection from enzymatic digestion in serum-containing media during the 24-hour incubation period, thereby bolstering its potential transfection utility.
Heparin is a polyanionic sulfated glycosaminoglycan polysaccharide that is commonly used in displacement assays to confirm the reversible capture-release nature of non-covalent, ionic complexes (Ryu et al. 2011).28 In this assay (Fig. 2D), heparin sodium salt was added to outcompete the binding capacity of the cationic peptide (W-R9 and R9) for the anionic pDNA (pUC19), thereby releasing the pDNA vector in its free form. The heparin displacement assay validates the reversibility of the peptide:pDNA ionic complex, that is applicable to the capture and release of pDNA for gene expression. Heparin competitive binding displacement of the pUC19 pDNA vector from the peptides, W-R9 (Fig. 2D) and R9 (Fig. S1, ESI), in a dose-dependent (1-10 mg) manner, was confirmed by the reappearance of the pDNA band upon heparin addition, when compared to the peptide:pDNA ionic complex (10:1 N:P ratio) without heparin. The fainter pUC19 band intensities with lower-dose (1 µg) compared to higher-doses (2.5-10 µg) of heparin indicates that some peptide remains bound to the pUC19 at lower heparin treatment conditions, and with complete displacement of pDNA with increased addition of heparin. This result aligns with literature precedence, showing the ability of heparin to displace peptides from pDNA vectors (Ryu et al. 2011).28 Overall, this result indicates that W-R9 forms a reversible ionic complex with a pUC19 pDNA, that effectively functions as a capture and release system for gene delivery.
Transmission electron microscopy (TEM) imaging (Fig. 3) of the peptide:pDNA ionic complexes (FITC-W-R9 combined with pUC19 at a 10:1 N:P ratio in milliQ H2O) was next conducted to gain a visual representation of the relative sizes and shapes of the (nano)particles with (Fig. 3B) and without (Fig. 3A) CaCl2, functioning as ionic stabilizer (Alkhamy et al. 2016 and Baoum et al. 2012).25,29 The peptide:pDNA complex alone shows a disordered aggregated assembly of large particles, whereas CaCl2 condensed the peptide:pDNA ionic complex into smaller (< 200 nm), discrete nanoparticles that may be applicable to gene delivery. In the absence of CaCl2, the peptide:pDNA complex appears to form larger aggregated structures, that may impede cell uptake and reduce gene delivery efficacy (Cultrara et al. 2019).30 Therefore, the ability to condense stable and reversible peptide:pDNA ionic complexes into small, discrete and uniform nanoparticles is another important requirement for effective gene delivery (Su et al. 2022).31 Various conditions exist for condensing pDNA-based ionic complexes, including CaCl2, that also improves cell uptake efficiency when used in combination with cell penetrating peptides (Su et al. 2022, Alkhamy et al. 2016 and Baoum et al. 2012).25,29,31 Furthermore, CaCl2 has also been reported to enhance the endosomal escape capacity of nucleic acid cargo resulting in enhanced transfection efficacy (Khondee et al. 2011).32 Mechanistic studies revealed the combined Ca2+ effects on the peptide:pDNA ionic complex that promotes membrane destabilization and pore formation for enhancing cell uptake, while also promoting endosomal rupture and release of pDNA for gene expression (Alkhamy et al. 2016).25 Thus, CaCl2 has been effectively shown to condense the peptide:pDNA ionic complexes into stable nanoparticles that improves transfection efficiency.
Cell Biology of Peptide:pDNA Nanoparticles
A preliminary cell uptake study was conducted to test the transfection capabilities of the fluorescein-labeled polyarginine-derived GRP78-targeting peptide (FITC-W-R9) in combination with a mock pBR322 vector within the DU145 prostate cancer cells (Fig. 4). Confocal fluorescence microscopy was used to confirm cell uptake and determine the subcellular localization of the polyarginine-derived GRP78-targeting peptide:pDNA (FITC-W-R9:pBR322). Punctate areas of green fluorescence (green arrows, Fig. 4) were detected in the cytosol of transfected DU145 cells. This observation suggests the entrapment of the peptide-based pDNA formulation in vesicle-type endosomes may restrict pDNA release for gene expression. This result also aligns with the reported clathrin-receptor mediated endocytosis cell uptake mechanism of GRP78-targeting peptides (Kim et al. 2006 and Liu et al. 2007).33,34 This pathway has been associated with the active peptide-binding and ATPase domains of csGRP78, that favor formation of clathrin-coated pits that detach from the plasma membrane to form intracellular vesicles via receptor-mediated endocytosis of peptide ligands (Liu et al. 2007).34 Although polyarginine-derived GRP78-targeting peptides can improve cell uptake (Joseph et al. 2014),35 intracellular entrapment may restrict its drug (gene) delivery efficacy.
Transfection efficiency was initially tested with a reporter Green Fluorescent Protein (GFP)-expressing pDNA (pGFP) in combination with the polyarginine-derived GRP78-targeting peptide (W-R9) that formed the peptide:pDNA (W-R9:pGFP) nanoparticles. A direct comparison of the peptide-based (W-R9) pGFP transfection efficiency with the benchmark Lipofectamine™ 3000 cationic lipid transfection agent indicated poor (<5%) GFP expression signaling with the peptide:pDNA conditions (Fig. 5B), whereas Lipofectamine™ 3000 effected noticeable (25-35%) GFP detection (Fig. 5A) according to fluorescence microscopy (Fig. S2, ESI). The insignificant peptide-based pDNA transfection efficiency may be due to the large, aggregated particles apparent by TEM imaging (Fig. 3A), that inhibits cell uptake (Cutrara et al. 2019),30 or incomplete endolysosomal escape, that is consistent with the punctate fluorescent (FITC) nanoparticles suggestive of peptide;pDNA entrapment within vesicle-type endosomes in the DU145 cells (Fig. 4).
A variety of additives, commonly used to improve peptide:pDNA transfection efficiency (Baoum et al. 2012, Ibanez et al. 1996, Yang et al. 2009, Griesenbach et al. 2012 and Alhakamy et al. 2013 and 2016),25,29,36-39 were screened and selected to optimize the peptide-based (W-R9) transfection conditions with the reporter pGFP vector within the DU145 cells. For example, CaCl2 was added to condense the peptide:pDNA formulation into stable nanoparticles via favourable electrostatic interactions (Fig. 3B), that was also anticipated to enhance cell uptake (Alhakamy et al. 2016 and Baoum et al. 2012).25,29 Moreover, CaCl2 has been used to increase endosomal escape of cationic cell-penetrating peptides and pDNA nanoparticles (Alhakamy et al. 2013).39 The addition of CaCl2 (50, 150, and 300 mM) exhibited modest effects on the peptide-based pGFP transfection, and resulted in apparent toxicity to the DU145 cells, especially at higher concentrations (300 mM) and extended (48-72 h.) incubations (Fig. S3, ESI). Trans-cyclohexane-1,2-diol (TCHD) was also tested for its ability to increase peptide-based transfection efficiency with the pGFP reporter. TCHD has been shown to enlarge the nuclear pores, thereby collapsing the permeability barrier across the nuclear membrane, for nuclear uptake of larger biomacromolecules, including pDNA for gene expression (Griesenbach et al. 2012).38 The addition of TCHD (0.5, 1.0, 2.0 %) also moderately improved the peptide-based pGFP transfection efficiency according to fluorescence microscopy, while producing significant toxicity to the DU145 cells, even at low doses (Fig. S4, ESI). Due to cell toxicity, CaCl2 and TCHD were discontinued in the optimization of peptide-based pDNA transfection studies.
Spermidine and chloroquine were next evaluated to optimize the peptide-based transfection conditions with the reporter pGFP in the GRP78-presenting DU145 cells (Wong-Baeza et al. 2010).40 Spermidine is a polycationic polyamine that aides in the condensation of nucleic acids and favors the intracellular release of pDNA for gene expression (Ibanez et al. 1996).36 Chloroquine, functions as a lysosomotropic agent that increases the lysosomal pH, thereby directly disrupting endosomal membranes contributing to endolysosomal escape of cargo for intracellular activity (Yang et al. 2009).37 Transfection studies have used chloroquine and spermidine in combination with liposomal-based gene delivery agents, that served to improve transfection efficiency resulting in enhanced gene expression (Moradpour et al. 1996 and Zhang et al. 2023).41,42 In this study, the peptide-based (W-R9) transfection efficiency of pGFP was examined in the presence and absence of chloroquine and spermidine, and compared to the benchmark Lipofectamine 3000 transfection reagent (Fig. 5). The combination of chloroquine and spermidine (70 and 17.5 µM, respectively) improved the transfection efficiency of the peptide:pDNA complex, resulting in enhanced pGFP expression (Fig. 5C) compared to the peptide:pDNA transfection conditions that were absent of the additives and displayed very little, faint fluorescence signaling (Fig. 5B). Chloroquine and spermidine also maintained good cell viability compared to the previously tested peptide-based pGFP transfection conditions (Figs. S3 and S4, ESI). In comparison, the pGFP transfection conditions with chloroquine and spermidine, but absent of peptide, displayed background GFP fluorescence, as negative control (Fig. 5D). Alternatively, the Lipofectamine:pGFP transfection condition promoted GFP expression, as positive control (Fig 5A). This outcome demonstrates the ability for the select additives, chloroquine and spermidine, to improve the peptide:pDNA transfection efficiency, while maintaining cell viability at low effective concentrations underscoring their utility as safe and effective additives for promoting peptide-based gene delivery.
The optimized peptide-based (W-R9) pGFP transfection conditions with chloroquine and spermidine were also used to confirm the GRP78-dependent mechanism of cell uptake resulting in GFP expression (Fig. 6). In competition with the primary GRP78/Bip monoclonal antibody (1D6F7), selected to block the peptide-binding domain (351-654) of csGRP78, the pGFP expression was diminished in the peptide-based transfection with chloroquine and spermidine (Fig. 6B). In comparison, the peptide-based transfection conditions with chloroquine and spermidine, in the absence of anti-GRP78 displayed an increase in GFP signaling (Fig. 6A). Alternatively, the negative control pGFP transfection conditions with chloroquine and spermidine alone, produced negligible GFP signaling (Fig. 6C). Significantly, this result provides direct evidence of the GRP78-dependent peptide:pDNA cell uptake mechanism that results in pGFP expression within the DU145 cells (Fig. 6A vs. 6B). Therefore, the GRP78-targeting polyarginine peptide (W-R9) functions as a gene delivery system within csGRP78-presenting tumors for applications in the cancer-targeted delivery of gene (pDNA) therapeutics.
The translational, anti-cancer utility of the optimized peptide-based transfection conditions was subsequently examined with a plasmid vector applicable to cancer-targeted gene therapy. The p53 pDNA expression vector was used to produce wild-type tumor suppressor protein p53 within the representative DU145 prostate cancer (PCa) cell line expressing the csGRP78 biomarker (Arap et al. 2004)19 and mutant tumor tp53 oncogene (Chappell et al. 2012).43 The tumor suppressor protein, p53, is long-regarded as the guardian of the human genome, acting as a critical transcription factor of multiple (~500) gene targets, including those involved in DNA repair, cell cycle arrest, senescence and apoptosis in transformed cancer cells (Lane 1992).44 However, the anti-tumor activity of p53 is abolished in about half of all cancers due to excessive mutations and oncogenic tumor p53 signaling driving cancer cell proliferation, spread and therapy resistance (Muller et al. 2014).45 Therefore, an effective gene therapy strategy will activate wild-type (wtp53) gene expression to restore tumor suppression, resulting in potent anti-cancer responses (Chappell et al. 2012 and Yu et al. 2004).43,46 The optimized peptide-based (W-R9) pDNA transfection conditions with chloroquine and spermidine were used in a preliminary study, to express the wild-type p53 tumor suppressor within the DU145 PCa cells, known to express mutant tp53 variants (Chappell et al. 2012).43 Western blot indicated the protein expression levels of the wild-type p53 isoforms, detected significantly with the control Lipofectamine™ 3000 transfection agent (Fig. 7, lane 2), and to a lesser, but noticeable extent with the optimized peptide-based transfection conditions (Fig. 7, lane 4). Interestingly, the peptide-based transfection conditions in the absence of the additives, chloroquine and spermidine, did not produce detectable levels of p53 (Fig. 7, lane 3), that was consistent with the poor pGFP transfection efficiency observed for the W-R9 peptide alone (Fig. 5B). However, in combination with chloroquine and spermidine additives, an enhancement in peptide-based transfection efficiency is observed (Figs., 5C, 6A and 7, lane 4). Alternatively, that additives chloroquine and spermidine in the absence of peptide (W-R9) do not enable protein expression (Figs., 5D, 6C and 7, lane 5). Therefore, the polyarginine-derived GRP78-targeting peptide (W-R9), with chloroquine and spermidine additives, enhances gene (pDNA) delivery directly within the GRP78-overexpressing DU145 prostate cancer cells. These exploratory results also suggest the ability to restore the functional, anti-tumor responses of the wild-type p53 tumor suppressor directly within the DU145 cells, and to overcome the oncogenic effects of mutant (tp53) biomarkers, leading towards the innovation of a promising cancer-targeted gene therapy approach.